Clinical trial
VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid…
NCT00354276 · Vion Pharmaceuticals, Industry · Unknown status
Key facts
| NCT number | NCT00354276 |
|---|---|
| Title | VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia |
| Official title | A Phase II Study of Cloretazine® (VNP40101M) for Elderly Patients With De Novo Poor Risk Acute Myelogenous Leukemia |
| Lead sponsor | Vion Pharmaceuticals, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | cytarabine, laromustine |
| Enrollment | 85 |
| Start date | May 1, 2006 |
| Primary completion | Dec 1, 2008 |
| First posted | Jul 20, 2006 |
| Last update posted | Jan 10, 2014 |
| Countries | France, United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: